What is the long-term trend for OptimizeRx's net additions (releases) charged to costs and expenses?

Over 4 years (2021 to 2025), OptimizeRx's net additions (releases) charged to costs and expenses has grown at a -100.0% compound annual growth rate (CAGR), from $80K to $0.

OptimizeRx OPRX Net additions (releases) charged to costs and expenses

Net additions (releases) charged to costs and expenses at other companies

T-Mobile USTMUS

$426M+31.9%

Mercado LibreMELI

$1.24B+106%

Robinhood Markets, Inc.HOOD

$36M+50.0%

Willdan GroupWLDN

$2.5K—

QuidelOrtho CorporationQDEL

$137.53M+13.1%

Cogent Communications HoldingsCCOI

$2.51M-37.9%

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's net additions (releases) charged to costs and expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's net additions (releases) charged to costs and expenses?: OptimizeRx (OPRX) reported net additions (releases) charged to costs and expenses of $0 in Q1 2026.
What is the long-term trend for OptimizeRx's net additions (releases) charged to costs and expenses?: Over 4 years (2021 to 2025), OptimizeRx's net additions (releases) charged to costs and expenses has grown at a -100.0% compound annual growth rate (CAGR), from $80K to $0.